HeartBeam Submits FDA Pre-Sub for 12-Lead Heart Attack Detection, Extends Cash Runway

Q2 2026 update: commercial launch gains traction, cash burn falls, and MI detection moves a step closer to pivotal trial

BEATW · Earnings Call · 2026-08-13

Clinical Momentum and a New Regulatory Frontier

HeartBeam’s Q2 2026 call was anchored by a single, high-stakes event: the company submitted its FDA pre-sub for heart attack detection the very morning of the call. As Executive Chairman Richard Ferrari put it, “I am happy to tell you that we actually did submit the pre-sub today.” — Richard Ferrari, CEO · 2026-08-13 This is the first concrete step toward a probability of success milestone for the company’s core MI-detection platform. The submission follows the completed ALIGN-ACS pilot (134 patients, enrolled in under four months) and the HEADSTART-ACS study (500-patient, already past 50% enrollment in under three months). The company is also leveraging a real world evidence study from the Indonesian government partnership, which could be a key differentiator in international markets. Ferrari emphasized the technology’s uniqueness:

There is just no other technology that we are aware of that does exactly what we are doing.
Richard Ferrari, CEO · 2026-08-13

With 25 issued patents and a growing body of clinical evidence, HeartBeam is positioning itself as the first to offer a true 12-lead EKG in a handheld form factor for heart attack detection. The FDA has 75 days to respond to the pre-sub, and management is “cautiously optimistic” about starting a pivotal trial by year-end, potentially via a 510(k) pathway.

Commercial Launch: From Agreements to Workflows

On the commercial front, the company has moved beyond signing distribution agreements. It now has contracts covering all four targeted U.S. geographies—New York, Dallas, South Florida, and Southern California—and has shipped initial orders. The focus has shifted to integrating HeartBeam into commercial readiness workflows at concierge practices. Ferrari described a new patient-intake program where every new patient gets a baseline 12-lead EKG, making it easier to deploy the card to at-risk patients. The “green shoots” are real, but management is careful not to overpromise. Tim Cruickshank noted, “We have extended our cash runway a bit further into 2027 than we previously indicated.” — Tim Cruickshank, CFO · 2026-08-13 The concierge market alone is estimated at ~1.9 million patients, with sub-30,000 needed for cash-flow breakeven.

Financial Discipline and a Tightened Cost Profile

Q2 net cash used in operating activity was $3.3 million, a 7% reduction QoQ and 3% YoY. The company has aggressively cut costs—pausing tangential contractor projects, using AI tools, and having employees take shares in lieu of cash bonuses. This drove net cash burn down, allowing a step-down to sub-$2.5 million per quarter by Q4, barring the start of the pivotal MI trial. Net loss for the quarter was $5.0 million, but that includes $0.9 million in one-time leadership transition costs (stock-based vesting and severance). Excluding those, the underlying net loss would have been ~$4.1 million, down 12% QoQ. Cash, equivalents, and restricted cash stood at $8.8 million as of June 30, with an extended runway into 2027.

What Changed and Why It Matters

This wasn’t a quarter of dramatic operational shifts, but rather one of execution and positioning. The FDA pre-sub submission is a tangible step toward the company’s biggest catalyst. The commercial launch, while early, is moving from pilot to workflow integration. The cost discipline buys time to reach these milestones without excessive dilution. The real risk remains execution—enrollment speed in the pivotal trial and converting concierge interest into recurring revenue. But the company is doing exactly what a pre-revenue medtech should: advancing clinical evidence, building a moat, and extending its cash runway. With no price data in this report (as of yet), the market’s reaction to this call remains to be seen, but the narrative is building. For now, HeartBeam’s story is one of incremental but meaningful progress on all fronts, with a clear path to a pivotal catalyst by year-end.